钠-葡萄糖共转运蛋白2抑制剂治疗心力衰竭的研究进展及机制探讨  

Research results and mechanism of sodium glucose cotransporter 2 inhibitors in the treatment of heart failure

作　　者：黄华华 田涛[2] 张冬梅[2] 马文元 Huang Huahua;Tian Tao;Zhang Dongmei;Ma Wengyuan(Shandong First Medical University,Jinan 250024,China;Department of Geriatrics,Linyi People′s Hospital,Linyi 276000,China)

机构地区：[1]山东第一医科大学,济南250024 [2]临沂市人民医院老年科,临沂276000

出　　处：《中国医师杂志》2022年第4期637-640,F0003,共5页Journal of Chinese Physician

摘　　要：钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)是一类新型降糖药,可抑制葡萄糖重吸收而起到降糖作用。近期研究发现,SGLT2i不仅能降低血糖,对心血管系统也有保护作用,可使心力衰竭患者受益,但具体作用机制现仍未完全阐明。本文旨在总结SGLT2i在心力衰竭领域最新的研究成果,分析可能存在的机制,以便指导临床。Sodium glucose cotransporter 2 inhibitor(SGLT2i)emerged as a new hypoglycemic agent,which can inhibit glucose reabsorption and thus play a hypoglycemic role.Recent studies have shown that SGLT2i not only lowers blood glucose,but also has a protective effect on the cardiovascular system,which may benefit patients with heart failure.The specific mechanism of action is still not fully elucidated.This paper aims to summarize the latest research results of SGLT2i in the treatment of heart failure,and analyze the possible mechanisms for clinical guidance.

关 键 词：糖尿病 2型 心力衰竭 钠-葡萄糖共转运蛋白2抑制剂 

分 类 号：R541.6[医药卫生—心血管疾病]